Medicare Part D coverage gap implementation, implementation of Medicaid rebate increases & expansions - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Oral oncology treatment coverage by insurance companies - HR 2366, Drug Coverage Parity Act of 2009
Duration: June 1, 2009
to
December 17, 2010
General Issues: Medicare/Medicaid , Health Issues , Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Budget/Appropriations , Trade (Domestic & Foreign) , Pharmacy
Spending: about $930,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2009: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Kimberly Linthicum Legislative Director, Rep Bob Franks (1997-2000)
Legislative Correspondent, Rep Charles Taylor (1997)
Legislative Correspondent, Rep Bill Martini (1995-1996)
Leg Director, Rep Bob Franks (1997-2000)
Leg Dir, Rep Bob Franks (1997-2000)
" " Leg Correspondent, Rep Charles Taylor (1997)
Leg Correspondent, Rep Bill Martini (1995-1996)
Leg Corr, Rep Charles Taylor (1997)
Leg Corr, Rep Bill Martini (1995-1996)
PAT BARNETT n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2010
OSI Pharmaceuticals, Inc. in-house lobbying effort was terminated on Dec. 15, 2010
Original Filing: 300333913.xml
3rd Quarter, 2010
In Q3, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on Oct. 19, 2010.
Original Filing: 300329589.xml
Lobbying Issues
Medicare Part D coverage gap implementation, implementation of Medicaid rebate increases & expansions - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Lobbying Issues
Oral oncology treatment coverage by insurance companies - HR 2366, Drug Coverage Parity Act of 2009
2nd Quarter, 2010
In Q2, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on July 20, 2010.
Original Filing: 300296373.xml
Lobbying Issues
Health care reform implementation - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap implementation, implementation of Medicaid rebate increases & expansions - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Lobbying Issues
Patent settlement arrangements - American Jobs and Closing Tax Loopholes Act of 2010 (HR 4213)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Implementation of tax on pharmaceutical manufacturers - Patient Protection and Affordable Care Act (HR 3590/PL 111-148) and Health Care and Education Reconciliation Act of 2010 (HR 4872/PL 111-152)
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2010
In Q1, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on April 20, 2010.
Original Filing: 300274899.xml
Lobbying Issues
Health care reform, price controls for pharmaceuticals, importation amendments - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009, HR 4872 The Health Care and Education Affordability Reconciliation Act of 2010 & HR 3200 America's Affordable Health Choices Act of 2009
Physician Payment Sunshine provisions - S. 301
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap, Medicaid rebate increases & expansions - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009, HR 3200 America's Affordable Health Choices Act of 2009 & HR 4872 The Health Care and Education Affordability Reconciliation Act of 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent settlement arrangements - S 369, HR 1706, HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Tax on pharmaceutical manufacturers - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009, HR 4872 The Health Care and Education Affordability Reconciliation Act of 2010
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2009
In Q4, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on Jan. 19, 2010.
Original Filing: 300238746.xml
Lobbying Issues
Health care reform, price controls for pharmaceuticals, importation amendments - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009 & HR 3200 America's Affordable Health Choices Act of 2009
Physician Payment Sunshine provisions - S. 301
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap, Medicaid rebate increases & expansions - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009 & HR 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent settlement arrangements - S 369, HR 1706, HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Tax on pharmaceutical manufacturers - HR 3590 Patient Protection and Affordable Care Act, S 1796 America's Healthy Future Act of 2009
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2009
In Q3, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on Oct. 20, 2009.
Original Filing: 300220973.xml
Lobbying Issues
Health care reform, price controls for pharmaceuticals - S. _ Americas Healthy Future Act of 2009 (no bill # yet), HR 3200 America's Affordable Health Choices Act of 2009
Physician Payment Sunshine provisions - S. 301
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap, Medicaid rebate increases & expansions - S _ Americas Healthy Future Act of 2009 (no bill # yet) and HR 3200 America's Affordable Health Choices Act of 2009
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Amendments relating to the importation of drugs: H.R. 2892, Department of Homeland Security Appropriations Act, 2010; H.R. 2997, Agriculture, Rural Development, Food and Drug Administration and Related Agencies Appropriations Act, 2010; S.1298, Department of Homeland Security Appropriations Act, 2010; S.1406, Agriculture, Rural Development, Food and Drug Administration and related Agencies Appropriations Act, 2010
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Patent settlement arrangements - S 369, HR 1706
Reforms to the patent system - S 515, HR 1260
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Tax on pharmaceutical manufacturers - S _ America's Healthy Future Act of 2009 (No bill # yet)
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2009
OSI Pharmaceuticals, Inc. amended a lobbying report for in-house lobbying in Q22009 on July 26, 2009
Original Filing: 300195613.xml
Lobbying Issues
Health care reform, price controls for pharmceuticals - S. _ Affordable Health Choices Act (No bill # yet), "Tri-Committee Health Reform Discussion Draft" (No bill #)
Physician Payment Sunshine provisions - S. 301
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap, Medicaid rebate increases and expansions - S._ Affordable Health Choices Act (no bill # yet) Tri-Committee Health Reform Discussion Draft (no bill #)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Amendments relating to the importation of drugs - Department of Homeland Security Appropriations Act, 2010 (H.R. 2892; S. 1298)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Patent settlement arrangements - S. 369, H.R. 1706
Reforms to the patent system - S. 515, H.R. 1260
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2009
In Q2, OSI Pharmaceuticals, Inc. had in-house lobbyists. The report was filed on July 17, 2009.
Original Filing: 300184498.xml
Lobbying Issues
Health care reform, price controls for pharmceuticals - S. _ Affordable Health Choices Act (No bill # yet), "Tri-Committee Health Reform Discussion Draft" (No bill #)
Physician Payment Sunshine provisions - S. 301
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Medicare Part D coverage gap, Medicaid rebate increases and expansions - S._ Affordable Health Choices Act (no bill # yet) Tri-Committee Health Reform Discussion Draft (no bill #)
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Amendments relating to the importation of drugs - Department of Homeland Security Appropriations Act, 2010 (H.R. 2892; S. 1298)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Patent settlement arrangements - S. 369, H.R. 1706
Reforms to the patent system - S. 515, H.R. 1260
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2009
OSI Pharmaceuticals, Inc. filed a lobbying registration on June 28, 2009 for in-house lobbying efforts, effective June 1, 2009.
Original Filing: 300171854.xml
Issue(s) they said they’d lobby about: Medicare Part D (Medicare Prescription Drug Benefit), Medicare reimbursement for drugs & biologics, health insurance reform (ERISA & HIPPA), Medicaid rebate, 340b pricing program, importation, patent reform (Hatch-Waxman Act), corporate taxation, FDA funding, FDA authority, prescription drug user fees, PTO funding .
2nd Quarter, 2009
OSI Pharmaceuticals, Inc. filed a lobbying registration on June 28, 2009 for in-house lobbying efforts, effective June 1, 2009.
Original Filing: 300171868.xml
Issue(s) they said they’d lobby about: Medicare Part D (Medicare Prescription Drug Benefit), Medicare reimbursement for drugs & biologics, health insurance reform (ERISA & HIPPA), Medicaid rebate, 340b pricing program, importation, patent reform (Hatch-Waxman Act), corporate taxation, FDA funding, FDA authority, prescription drug user fees, PTO funding .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...